The FDA has approved a home prescription brain neuromodulation therapy device as an adjunctive treatment for treatment-resistant depression in adults. The ProlivRx device was developed by Neurolief and is the first home prescription device of its type. The manufacturer announced the approval on Tuesday. The therapy provides focal neuromodulation of the brain. The device serves as an adjunct to existing depression treatment. The information was published by the MedPage Today portal.